NCT04965662View on ClinicalTrials.gov

The Role of Home Packs of HIV PEPSE in High Risk Individuals

PHASE4CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 16, 2021

Study Completion Date

March 16, 2021

Conditions
HIV-1-infection
Interventions
DRUG

Maraviroc

Maraviroc 300 mg, TWO tablets once daily.

DRUG

Truvada

Truvada one tablet once daily

Trial Locations (1)

SE1 9RT

Guy's & St. Thomas' NHS Foundation Trust, London

Sponsors
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

Guy's and St Thomas' NHS Foundation Trust

OTHER

NCT04965662 - The Role of Home Packs of HIV PEPSE in High Risk Individuals | Biotech Hunter | Biotech Hunter